Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 lot-to-lot consistency study of MenACWY vaccine
2014-003504-79Phase 3
- Sponsor
- Novartis
- Start
- Oct 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Meningococcal ACWY conjugate vaccine in meningococcal disease, meningococcal meningitis and meningococcemia (4 arms), sponsored by Novartis. Primary endpoint: Lot-to-lot consistency of MenACWY by hSBA GMT vaccine group ratios.
02
Drugs
Meningococcal ACWY conjugate vaccine
03
Conditions
meningococcal diseasemeningococcal meningitismeningococcemia
Beyond the preview
Go deeper on 2014-003504-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003504-79.